



1655/2

IFW

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Bastian Nuyen et al.  
Serial No. : 09/622,433  
Filed : May 10, 2002  
Title : PHARMACEUTICAL FORMULATION OF A DIDEMNIN COMPOUND

Art Unit : 1655  
Examiner : Randall O. Winston  
Conf. No. : 4574

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request.

This statement is being filed after a first Office action on the merits, but before receipt of a final Office action or a Notice of Allowance. A check for \$180 in payment of the late submission fee of §1.17(p) is enclosed. Please apply any other charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 14620-012US1.

Respectfully submitted,

Date: March 26, 2007

John T. Kendall, Ph.D.  
Reg. No. 50,680

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906  
21593262.doc

## CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit

March 26, 2007


Signature

Typed or Printed Name of Person Signing Certificate

03/28/2007 EEKUBAY1 00000005 03622433

01 FC:1806

180.00 DP




<b>Substitute Form PTO-1449</b> (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	<b>U.S. Department of Commerce Patent and Trademark Office</b>	<b>Attorney's Docket No.</b> 14620-012US1	<b>Application No.</b> 09/622,433
	<b>Applicant</b> Bastian Nuyen et al.		
	<b>Filing Date</b> May 10, 2002	<b>Group Art Unit</b> 1655	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	6,890,904	05/10/05	Wallner et al.			
	AB	7,064,105	06/20/06	Joullié et al.			
	AC						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AD	WO 00/71135	11/30/00	WIPO				
	AE	WO 01/35974	05/25/01	WIPO				
	AF	WO 02/02596	01/10/02	WIPO				
	AG	WO 02/30441	04/18/02	WIPO				
	AH							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AI	Bennett, J. Claude, and Fred Plum, eds. <i>Cecil Textbook of Medicine</i> , "Part XIV – Oncology", W. B. Saunders & Company, 20th Ed., Vol. 1, pp. 1004-1010 (1996).
	AJ	Committee for Proprietary Medicinal Products (CPMP) - "Note for Guidance on Evaluation of Anticancer Medicinal Products in Man", <i>The European Agency for the Evaluation of Medicinal Products</i> , EMEA, London, England, CPMP/EWP/205/95 rev. 1 corr, 14 pages, (2001).
	AK	DeVita, Jr., Vincent T, Samuel Hellman, and Steven A Rosenberg, eds. <i>Cancer: Principles and Practice of Oncology</i> , "Section 3 - Cancer of the Pancreas", Lippincott Williams & Wilkins, 7 <sup>th</sup> Ed., 7 pages, (2005).
	AL	Draetta, Giulio et al., "Section V. Topics in Biology – Chapter 25. Cell Cycle Control and Cancer", <i>Annual Reports in Medicinal Chemistry</i> , pp. 241-248, 1996.
	AM	Geldof et al., "Cytotoxicity and Neurocytotoxicity of New Marine Anticancer Agents Evaluated Using in Vitro Assays", <i>Cancer Chemother. Pharmacol.</i> ; 44 321-318, (1999).
	AN	Hansen, Richard et al., "Continuous 5-Fluorouracil (5FU) Infusion in Carcinoma of the Pancreas: A Phase II Study", <i>American Journal of Medical Science</i> , 295:91-93, (1988).
	AO	Kerbel, Robert S., "What is the Optimal Rodent Model for Anti-Tumor Drug Testing?", <i>Cancer and Metastasis Reviews</i> , 17: 301-304, (1999).
	AP	O'Neil, Maryadele J., Ann Smith and Patricia E. Heckelman, eds. <i>The Merck Index – An Encyclopedia of Chemicals, Drugs, and Biologicals</i> , Merck & Co., Inc., 13 <sup>th</sup> Ed., page 1791, (2001).
	AQ	Raymond, N. Ady-Vago et al., "25 <sup>th</sup> Congress of the European Society of Medicinal Oncology", Hamburg, Germany, 13-17 October 2000, reported in the <i>Annals of Oncology</i> , Kluwer Academic Publishers, Supplement 4 to Volume 11, Abstract 610PD, 2 pages, (2000).

<b>Examiner Signature</b> /Randall Winston/	<b>Date Considered</b> 11/05/2012
<b>EXAMINER:</b> Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14620-012US1	Application No. 09/622,433
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR § 1.98(b))		Applicant Bastian Nuyen et al.	
		Filing Date May 10, 2002	Group Art Unit 1655

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AR	Tempero, Margaret, et al., <i>Clinical Practice Guidelines in Oncology – v.2.2006</i> – “Pancreatic Adenocarcinoma” National Comprehensive Cancer Network, <a href="http://www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdf">http://www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdf</a> , 41 pages, (2006).
	AS	Urdiales et al., “Antiproliferative Effect of Dehydrodidemnin B (DDB), a Depsipeptide Isolated from Mediterranean Tunicates”, <i>Cancer Letters</i> , 102:31-37, (1996).
	AT	U.S. National Cancer Institute, U.S. National Institutes of Health, <a href="http://www.cancer.gov/cancertopics/factsheet/information/clinical-trials">www.cancer.gov</a> , “FactSheet”, 6 pages, <a href="http://www.cancer.gov/cancertopics/factsheet/information/clinical-trials">http://www.cancer.gov/cancertopics/factsheet/information/clinical-trials</a>
	AU	U.S. National Cancer Institute, U.S. National Institutes of Health, <a href="http://www.cancer.gov/cancertopics/pdq/treatment/pancreatic/healthprofessional">www.cancer.gov</a> , “Pancreatic Cancer (PDQ®): Treatment”, 3 pages, <a href="http://www.cancer.gov/cancertopics/pdq/treatment/pancreatic/healthprofessional">http://www.cancer.gov/cancertopics/pdq/treatment/pancreatic/healthprofessional</a>
	AV	Van-Boxtel, C. J., B. Santoso and I. R. Edwards, eds. <i>Drug Benefits and Risks: International Textbook of Clinical Pharmacology</i> , “Drug Development”, Chapter 9, pp. 91-102, (2001).

Examiner Signature /Randall Winston/	Date Considered 11/05/2012
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.W./